M. Tepel et al., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine, N ENG J MED, 343(3), 2000, pp. 180-184
Citations number
26
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Radiographic contrast agents can cause a reduction in renal fun
ction that may be due to reactive oxygen species. Whether the reduction can
be prevented by the administration of antioxidants is unknown.
Methods: We prospectively studied 83 patients with chronic renal insufficie
ncy (mean [+/-SD] serum creatinine concentration, 2.4+/-1.3 mg per decilite
r [216+/- 116 mu mol per liter]) who were undergoing computed tomography wi
th iopromide, a nonionic, low-osmolality contrast agent. Patients were rand
omly assigned either to receive the antioxidant acetylcysteine (600 mg oral
ly twice daily) and 0.45 percent saline intravenously, before and after adm
inistration of the contrast agent, or to receive placebo and saline.
Results: Ten of the 83 patients (12 percent) had an increase of at least 0.
5 mg per deciliter (44 mu mol per liter) in the serum creatinine concentrat
ion 48 hours after administration of the contrast agent: 1 of the 41 patien
ts in the acetylcysteine group (2 percent) and 9 of the 42 patients in the
control group (21 percent; P=0.01; relative risk, 0.1; 95 percent confidenc
e interval, 0.02 to 0.9). In the acetylcysteine group, the mean serum creat
inine concentration decreased significantly (P<0.001), from 2.5+/-1.3 to 2.
1+/-1.3 mg per deciliter (220+/-118 to 186+/-112 mu mol per liter) 48 hours
after the administration of the contrast medium, whereas in the control gr
oup, the mean serum creatinine concentration increased nonsignificantly (P=
0.18), from 2.4+/-1.3 to 2.6+/-1.5 mg per deciliter (212+/-114 to 226+/-133
mu mol per liter) (P<0.001 for the comparison between groups).
Conclusions: Prophylactic oral administration of the antioxidant acetylcyst
eine, along with hydration, prevents the reduction in renal function induce
d by iopromide, a nonionic, low-osmolality contrast agent, in patients with
chronic renal insufficiency. (N Engl J Med 2000;343:180-4.) (C)2000, Massa
chusetts Medical Society.